625826-69-9

Usage

Uses

Used in Pharmaceutical Research:
4-CHLOROMETHYL-2-(4-FLUORO-PHENYL)-5-METHYL-OXAZOLE is used as a research compound for exploring its potential biological and pharmacological properties. Its unique structure allows it to interact with various biological targets, making it a promising candidate for the development of new drugs and therapeutic agents.
Used in Chemical Research:
In the field of chemical research, 4-CHLOROMETHYL-2-(4-FLUORO-PHENYL)-5-METHYL-OXAZOLE serves as a valuable tool for studying the interactions of organic molecules with biological systems. Its structural features enable researchers to investigate the compound's reactivity, stability, and binding affinity to different molecular targets, contributing to a deeper understanding of molecular recognition and drug design principles.
Used in Drug Development:
4-CHLOROMETHYL-2-(4-FLUORO-PHENYL)-5-METHYL-OXAZOLE is employed as a lead compound in drug development, where its unique structural features can be further optimized to enhance its biological activity and selectivity. By modifying the chloromethyl, 4-fluoro-phenyl, and methyl groups, researchers can explore the compound's potential as a therapeutic agent for various diseases and conditions.
Used in Medicinal Chemistry:
In medicinal chemistry, 4-CHLOROMETHYL-2-(4-FLUORO-PHENYL)-5-METHYL-OXAZOLE is utilized as a building block for the synthesis of novel compounds with improved pharmacological properties. Its versatile structure allows for the incorporation of various functional groups and moieties, enabling the design of new molecules with enhanced potency, selectivity, and pharmacokinetic profiles.
Used in Chemical Synthesis:
4-CHLOROMETHYL-2-(4-FLUORO-PHENYL)-5-METHYL-OXAZOLE is also used as a synthetic intermediate in the preparation of other organic compounds. Its reactive chloromethyl group can be employed in various chemical reactions, such as nucleophilic substitution, to generate a wide range of derivatives with diverse applications in the chemical, pharmaceutical, and materials science industries.

InChI:InChI=1/C11H9ClFNO/c1-7-10(6-12)14-11(15-7)8-2-4-9(13)5-3-8/h2-5H,6H2,1H3

Upstream product

• 109544-28-7 2-(4-fluorophenyl)-4,5-dimethyloxazole 3-oxide 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 1107663-66-0 2-Amino-4-(4-{[(2S)-2-{[tert-butyl(dimethyl)silyl]oxy}propyl]oxy}phenyl)-6-({[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}thio)pyridine-3,5-dicarbonitrile 
• 1107662-73-6 2-Amino-6-({[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}thio)-4-(4-{[(2S)-2-hydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitrile 
• 1107662-82-7 2-Amino-6-{[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile 
• 1593269-66-9 tert-butyl 2-(4-{[{[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl] methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoate 
• 1593269-79-4 2-(4-{[{[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]-methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoic acid 
• 1026844-10-9 N-{3-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-benzyl}-hydroxylamine 

Relevant academic research and scientific papers

1,3-Oxazole-isoniazid hybrids: Synthesis, antitubercular activity, and their docking studies

A series of novel N′-([2-aryl-5-methyl-1,3-oxazole-4-yl]methylene)isonicotino/nicotino hydrazides 10a-l were prepared by the condensation reaction of 2-aryl-5-methyl-1,3-oxazole-4-carbaldehydes 8a-f with the corresponding isonicotino/nicotino hydrazides 9

Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of 7ii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties

We describe herein the design, syntheses and structure-activity relationships (SAR) of novel zwitter-ionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. In the previous report, we obtained compound 1 showing potent PPARα/γ dual agonistic activities, together with a great glucose lowering effect in the db/db mice. However, this compound possessed fatal issues such as potent cytochrome P450 (CYP)3A4 direct inhibitory activity. Thus, we carried out the medicinal optimization to improve these while maintaining the potent PPAR agonistic activity. As a result, the issues were addressed by changing the furan ring to a low lipophilic 1,3,4-oxadiazole ring. Additionally, these oxadiazole derivatives exhibited a significant decrease in plasma glucose and plasma triglyceride levels without marked weight gain.

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

In the quest for novel PPARα/γ co-agonists as putative drugs for the treatment of type 2 diabetes and dyslipidemia, we have used a structure-based design approach to identify propionic acids with a 1,5-disubstituted indole scaffold as potent PPARα/γ activ

A highly regioselective preparation of 4-chloromethyl-5-methyl-2-aryl-1,3- oxazoles

A facile highly regioselective process is described for the formation of 4-chloromethyl-1,3-oxazoles from 1,3-oxazole N-oxide/HCl salts. An explanation is presented for the high regioselectivity in deoxygenation-chlorination using POCl3 with HC

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5- lipoxygenase

Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO) inhibitors. Structure-activity relationship studies have demonstrated that electronegative substituents on the 2-phenyl portion of the oxazole tail increased the ex vivo potency of these